Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRB3 | P28472 | 20/20 | 0.46 |
| ▸ | GABRA2 | P47869 | 19/20 | 0.46 |
| ▸ | GABRB2 | P47870 | 19/20 | 0.46 |
| ▸ | GABRP | O00591 | 17/20 | 0.46 |
| ▸ | GABRD | O14764 | 17/20 | 0.46 |
| ▸ | GABRA1 | P14867 | 17/20 | 0.46 |
| ▸ | GABRB1 | P18505 | 17/20 | 0.46 |
| ▸ | GABRG2 | P18507 | 17/20 | 0.46 |
| ▸ | GABRA5 | P31644 | 17/20 | 0.46 |
| ▸ | GABRA3 | P34903 | 17/20 | 0.46 |
| ▸ | GABRA4 | P48169 | 17/20 | 0.46 |
| ▸ | GABRE | P78334 | 17/20 | 0.46 |
| ▸ | GABRA6 | Q16445 | 17/20 | 0.46 |
| ▸ | GABRG1 | Q8N1C3 | 17/20 | 0.46 |
| ▸ | GABRG3 | Q99928 | 17/20 | 0.46 |
| ▸ | GABRQ | Q9UN88 | 17/20 | 0.46 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14648758 | 0.90 | GABRB3 (0.47) | GABRB3GABRA2GABRB2GABRPGABRD | |
| SCHEMBL7025320 | 0.90 | GABRB3 (0.47) | GABRB3GABRA2GABRB2GABRPGABRD | |
| SCHEMBL4427641 | 0.87 | GABRB3 (0.44) | GABRB3GABRA2GABRB2GABRPGABRD | |
| SCHEMBL3970589 | 0.87 | GABRB3 (0.45) | GABRB3GABRA2GABRB2GABRPGABRD | |
| SCHEMBL5370578 | 0.86 | GABRB3 (0.44) | GABRB3GABRA2GABRB2GABRPGABRD | |
| SCHEMBL2835106 | 0.85 | GABRB3 (0.48) | GABRB3GABRA2GABRB2GABRPGABRD | |
| Butene-Fipronil SCHEMBL11992324 | 0.84 | GABRB3 (0.43) | GABRB3GABRA2GABRB2GABRPGABRD | |
| SCHEMBL28345400 | 0.84 | GABRB3 (0.43) | GABRB3GABRA2GABRB2GABRPGABRD | |
| SCHEMBL5201997 | 0.84 | GABRB3 (0.49) | GABRB3GABRA2GABRB2GABRPGABRD | |
| SCHEMBL19148223 | 0.84 | GABRB3 (0.42) | GABRB3GABRA2GABRB2GABRPGABRD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9066515-B2 | Topical formulations comprising 1-N-arylpyrazole derivatives and amitraz | MERIAL, INC. (US) | 2015-06-30 | — | — | US | disclosed |
| EP-1761502-B1 | N-PHENYLPYRAZOLE DERIVATIVES AS PESTICIDES | MERIAL LTD (US) | 2013-12-18 | — | — | EP | disclosed |
| EP-1569517-B1 | PESTICIDAL 5- (ACYLAMINO) PYRAZOLE DERIVATIVES | MERIAL LTD (US) | 2013-10-02 | — | — | EP | disclosed |
| EP-1599451-B1 | PESTICIDAL 1-ARYL-3-AMIDOXIME-PYRAZOLE DERIVATIVES | MERIAL LTD (US) | 2013-04-24 | — | — | EP | disclosed |
| US-8362086-B2 | Long acting injectable formulations | MERIAL LIMITED (US) | 2013-01-29 | — | — | US | disclosed |
| US-8362086-B2 | Long acting injectable formulations | MERIAL LIMITED (US) | 2013-01-29 | — | — | US | disclosed |
| US-20130023490-A1 | TOPICAL FORMULATIONS COMPRISING 1-N-ARYLPYRAZOLE DERIVATIVES AND AMITRAZ | MERIAL, INC. | 2013-01-24 | — | — | US | disclosed |
| US-8242161-B2 | Topical formulations comprising 1-N-arylpyrazole derivatives and amitraz | MERIAL LIMITED (US) | 2012-08-14 | — | — | US | disclosed |
| US-8242161-B2 | Topical formulations comprising 1-N-arylpyrazole derivatives and amitraz | MERIAL LIMITED (US) | 2012-08-14 | — | — | US | disclosed |
| US-8124642-B2 | Pesticidal N-phenylpyrazole derivatives | MERIAL LIMITED (US) | 2012-02-28 | — | — | US | disclosed |
| WO-2004050633-A1 | PESTICIDAL 1-AYL-3-AMIDOXIME-PYRAZOLE DERIVATIVES | BAYER CROPSCIENCE S.A. (FR) | 2004-06-17 | — | — | WO | disclosed |
| WO-2004049803-A1 | PESTICIDAL 5- (ACYLAMINO) PYRAZOLE DERIVATIVES | BAYER CROPSCIENCE S.A. (FR) | 2004-06-17 | — | — | WO | disclosed |
| WO-2004049797-A2 | PESTICIDAL SULPHONYLAMINOPYRAZOLES | BAYER CROPSCIENCE S.A. (FR) | 2004-06-17 | — | — | WO | disclosed |
| US-20040058819-A1 | Process for the preparation of pesticidal compounds | MERIAL, INC. | 2004-03-25 | — | — | US | disclosed |
| US-20040010016-A1 | Control of arthropods in animals | AVENTIS CROPSCIENCE, S.A. (FR) | 2004-01-15 | — | — | US | disclosed |
| US-6630499-B1 | Non-emetic 1-arylpyrazole for oral administration | AVENTIS CROPSCIENCE, S.A. (FR) | 2003-10-07 | — | — | US | disclosed |
| US-6531501-B1 | Veterinary parasiticide | AVENTIS CROPSCIENCE, S.A. (FR) | 2003-03-11 | — | — | US | disclosed |
| EP-1137639-A1 | CONTROL OF ARTHROPODS IN ANIMALS | AVENTIS CROPSCIENCE S.A. (FR) | 2001-10-04 | — | — | EP | disclosed |
| US-6160002-A | Control of arthropods in animals | RHONE-POULENC AGRO (FR) | 2000-12-12 | — | — | US | disclosed |
| WO-2000035884-A1 | CONTROL OF ARTHROPODS IN ANIMALS | AVENTIS CROPSCIENCE S.A. (FR) | 2000-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130023490-A1 | TOPICAL FORMULATIONS COMPRISING 1-N-ARYLPYRAZOLE DERIVATIVES AND AMITRAZ | MGAT2, MGAT1, MIF | GABRB3 2624/4885GABRA2 3005/4885GABRB2 2735/4885 |
| US-20040010016-A1 | Control of arthropods in animals | CTRL, CYP3A43, RPL41 | GABRB3 1493/4885GABRA2 2096/4885GABRB2 1859/4885 |
| US-20040058819-A1 | Process for the preparation of pesticidal compounds | HDHD5, KCNH1, HRH2 | GABRB3 2212/4885GABRA2 2404/4885GABRB2 1996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.